A Phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E

The molecular heterogeneity of acute myeloid leukemia (AML) underlies the wide variation in responses to standard therapy. This heterogeneity occurs at multiple regulatory steps affecting cell survival and proliferation.[1][1] We identified overexpression of the eukaryotic translation initiation